SCHEMBL19838574

SCHEMBL19838574

O=C1NCCCc2ccc(Cl)cc21

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 9/20 0.81
PARP1 P09874 6/20 0.81
F7 P08709 1/20 0.81
F3 P13726 1/20 0.81
JAK2 O60674 1/20 0.49
NTRK1 P04629 1/20 0.49
MET P08581 1/20 0.49
FGFR1 P11362 1/20 0.49
PRKACA P17612 1/20 0.49
KDR P35968 1/20 0.49
MAP2K2 P36507 1/20 0.49
FLT3 P36888 1/20 0.49
GSK3B P49841 1/20 0.49
MAP2K1 Q02750 1/20 0.49
MST1R Q04912 1/20 0.49
NTRK3 Q16288 1/20 0.49
NTRK2 Q16620 1/20 0.49
CAMK1D Q8IU85 1/20 0.49
PARP11 Q9NR21 4/20 0.47
PDPK1 O15530 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31743097 1.00 PARP10 (0.81) PARP10PARP1F7F3JAK2
SCHEMBL29676942 0.89 PARP10 (1.00) PARP10PARP1F7F3JAK2
SCHEMBL793493 0.89 PARP10 (1.00) PARP10PARP1F7F3JAK2
SCHEMBL23160447 0.86 PARP10 (0.60) PARP10PARP1F7F3GSK3B
SCHEMBL19838786 0.79 PARP10 (0.81) PARP10PARP1F7F3PARP11
SCHEMBL10201434 0.79 PARP1 (0.56) PARP10PARP1F7F3PARP11
SCHEMBL29712442 0.79 PARP10 (0.81) PARP10PARP1F7F3PARP11
SCHEMBL2062848 0.79 PARP10 (0.51) PARP10PARP1F7F3PARP11
SCHEMBL15830755 0.79 PARP10 (0.81) PARP10PARP1F7F3PARP11
SCHEMBL1760377 0.78 NTRK2 (0.74) PARP10PARP1F7F3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SUNOVION PHARMACEUTICALS INC. (US) 2021-11-30 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2019-06-27 US disclosed
WO-2018026371-A1 DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2018-02-08 WO disclosed
WO-2018026371-A1 DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS SUNOVION PHARMACEUTICALS INC. (US) 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190194163-A1 DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS SCN2A, HTR2A, HTR2C PARP10 2251/4885PARP1 2606/4885F7 4052/4885
US-11186564-B2 Dual NAV1.2/5HT2a inhibitors for treating CNS disorders SCN2A, HTR2A, HTR2C PARP10 2251/4885PARP1 2606/4885F7 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.